Moreover, as we previously showed that ATF2 plays a tumour-suppressive role in ER-positive endocrine sensitive breast cancer, the current data on an in vitro endocrine-resistant model highlights the dual role of ATF2 in breast cancer and suggests that ATF2 targeting has the potential of being effective novel therapeutic approach in endocrine-resistant breast cancer. Here, ATF2 is linked to breast cancer.